A prospective phase 2 clinical trial of a C5a complement inhibitor for acute GVHD with lower GI tract involvement

Involvement of lower gastrointestinal tract (LGI) occurs in 60% of patients with graft-versus-host-disease (GVHD). Complement components C3 and C5 are involved in GVHD pathogenesis. In this phase 2a study, we evaluated the safety and efficacy of ALXN1007, a monoclonal antibody against C5a, in patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Mehta, Rohtesh S., Ali, Haris, Dai, Yang, Yao, Bert, Overman, Bethany, Ratanatharathorn, Voravit, Gill, Saar, Socié, Gerard, Anderson, Kevin, Cahn, Jean Yves, Mujeebuddin, Arshad, Champlin, Richard, Shpall, Elizabeth, Holtan, Shernan G., Alousi, Amin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195122/
https://www.ncbi.nlm.nih.gov/pubmed/37202544
http://dx.doi.org/10.1038/s41409-023-01996-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10195122/
https://www.ncbi.nlm.nih.gov/pubmed/37202544
http://dx.doi.org/10.1038/s41409-023-01996-4

Ejemplares similares